Literature DB >> 25800127

Comparison of coronary artery bypass graft surgery and percutaneous coronary intervention in patients with diabetes.

Bora Toklu1, Sripal Bangalore.   

Abstract

OPINION STATEMENT: The optimal revascularization strategy in patients with diabetes is controversial. The Bypass Angioplasty Revascularization Investigation (BARI) trial, done more than a decade ago, suggested a mortality benefit of coronary artery bypass graft surgery (CABG) when compared with percutaneous coronary intervention (PCI) (with plain old balloon angioplasty) in the subgroup of patients with diabetes. In addition, several observational studies and meta-analyses similarly suggest a benefit of CABG over PCI in patients with diabetes. However, most of these studies compared CABG with PCI using balloon angioplasty, bare metal stents, or first-generation drug-eluting stents. In this review, we critically examine the data for optimal revascularization strategy in patients with diabetes and ask the question whether the currently available data from randomized trials that used outdated stents are applicable to current day practice.

Entities:  

Year:  2015        PMID: 25800127     DOI: 10.1007/s11936-015-0377-y

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  66 in total

1.  Argentine Randomized Study: Coronary Angioplasty with Stenting versus Coronary Bypass Surgery in patients with Multiple-Vessel Disease (ERACI II): 30-day and one-year follow-up results. ERACI II Investigators.

Authors:  A Rodriguez; V Bernardi; J Navia; J Baldi; L Grinfeld; J Martinez; D Vogel; R Grinfeld; A Delacasa; M Garrido; R Oliveri; E Mele; I Palacios; W O'Neill
Journal:  J Am Coll Cardiol       Date:  2001-01       Impact factor: 24.094

2.  2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

Authors:  Hani Jneid; Jeffrey L Anderson; R Scott Wright; Cynthia D Adams; Charles R Bridges; Donald E Casey; Steven M Ettinger; Francis M Fesmire; Theodore G Ganiats; A Michael Lincoff; Eric D Peterson; George J Philippides; Pierre Theroux; Nanette K Wenger; James Patrick Zidar; Jeffrey L Anderson
Journal:  Circulation       Date:  2012-07-16       Impact factor: 29.690

3.  Coronary revascularization (surgical or percutaneous) decreases mortality after the first year in diabetic subjects but not in nondiabetic subjects with multivessel disease: an analysis from the Medicine, Angioplasty, or Surgery Study (MASS II).

Authors:  Paulo R Soares; Whady A Hueb; Pedro A Lemos; Neuza Lopes; Eulógio E Martinez; Luis A M Cesar; Sergio A Oliveira; Jose A F Ramires
Journal:  Circulation       Date:  2006-07-04       Impact factor: 29.690

4.  Cost-effectiveness of percutaneous coronary intervention with drug eluting stents versus bypass surgery for patients with diabetes mellitus and multivessel coronary artery disease: results from the FREEDOM trial.

Authors:  Elizabeth A Magnuson; Michael E Farkouh; Valentin Fuster; Kaijun Wang; Katherine Vilain; Haiyan Li; Jaime Appelwick; Victoria Muratov; Lynn A Sleeper; Robin Boineau; Mouin Abdallah; David J Cohen
Journal:  Circulation       Date:  2012-12-31       Impact factor: 29.690

5.  Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial.

Authors:  Arie Pieter Kappetein; Stuart J Head; Marie-Claude Morice; Adrian P Banning; Patrick W Serruys; Friedrich-Wilhelm Mohr; Keith D Dawkins; Michael J Mack
Journal:  Eur J Cardiothorac Surg       Date:  2013-02-14       Impact factor: 4.191

6.  Eight-year mortality in the Emory Angioplasty versus Surgery Trial (EAST)

Authors:  S B King; A S Kosinski; R A Guyton; N J Lembo; W S Weintraub
Journal:  J Am Coll Cardiol       Date:  2000-04       Impact factor: 24.094

7.  Impact of diabetes on 10-year outcomes of patients with multivessel coronary artery disease in the Medicine, Angioplasty, or Surgery Study II (MASS II) trial.

Authors:  Eduardo Gomes Lima; Whady Hueb; Rosa Maria Rahmi Garcia; Alexandre Costa Pereira; Paulo Rogério Soares; Desiderio Favarato; Cibele Larrosa Garzillo; Ricardo D'Oliveira Vieira; Paulo Cury Rezende; Myrthes Takiuti; Priscyla Girardi; Alexandre Ciappina Hueb; José A F Ramires; Roberto Kalil Filho
Journal:  Am Heart J       Date:  2013-06-15       Impact factor: 4.749

8.  Frequency, management and follow-up of patients with acute coronary occlusions after percutaneous transluminal coronary angioplasty.

Authors:  C Simpfendorfer; J Belardi; G Bellamy; K Galan; I Franco; J Hollman
Journal:  Am J Cardiol       Date:  1987-02-01       Impact factor: 2.778

Review 9.  National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants.

Authors:  Goodarz Danaei; Mariel M Finucane; Yuan Lu; Gitanjali M Singh; Melanie J Cowan; Christopher J Paciorek; John K Lin; Farshad Farzadfar; Young-Ho Khang; Gretchen A Stevens; Mayuree Rao; Mohammed K Ali; Leanne M Riley; Carolyn A Robinson; Majid Ezzati
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

10.  Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis.

Authors:  Sripal Bangalore; Bora Toklu; Nicholas Amoroso; Mario Fusaro; Sunil Kumar; Edward L Hannan; David P Faxon; Frederick Feit
Journal:  BMJ       Date:  2013-11-08
View more
  1 in total

1.  BARI 2D: A Reanalysis Focusing on Cardiovascular Events.

Authors:  Saul M Genuth; Helen Vlachos; Maria Mori Brooks; John P Bantle; Bernard R Chaitman; Jennifer Green; Sheryl F Kelsey; Spencer B King; Robert McBane; Edward Y Sako; David J Schneider; Michael Steffes; Robert L Frye
Journal:  Mayo Clin Proc       Date:  2019-10-04       Impact factor: 7.616

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.